Summary
McKesson Corporation's (MCK) 2023 10-K filing highlights a year of strategic divestitures and acquisitions, with a notable focus on exiting European operations while strengthening its Prescription Technology Solutions (RxTS) segment. Revenues saw a 5% increase, primarily driven by growth in the U.S. Pharmaceutical segment, which benefited from market growth, specialty pharmaceuticals, and higher branded drug prices. This top-line expansion was partially offset by divestitures in the International segment and unfavorable foreign currency impacts. Despite revenue growth, gross profit experienced a 6% decrease, mainly due to the European divestitures and foreign currency impacts, though this was partially mitigated by gains in specialty pharmaceuticals and generics within the U.S. Pharmaceutical segment. The company demonstrated strong expense management, with total operating expenses decreasing by 28%, largely due to the prior year's significant remeasurement charges related to European divestitures. Diluted earnings per share from continuing operations saw a substantial increase, primarily attributed to the reduced remeasurement charges compared to the prior year and a lower share count resulting from ongoing share repurchase programs. Key strategic moves included the acquisition of Rx Savings Solutions, LLC, to enhance patient affordability and adherence solutions, and the formation of SCRI Oncology, LLC with HCA Healthcare to advance cancer research. The company also returned significant capital to shareholders through share repurchases and increased its quarterly dividend. Investors should monitor the ongoing opioid litigation, which continues to be a significant contingent liability, although the company has made substantial progress on settlements.
Financial Highlights
56 data points| Revenue | $276.71B |
| Cost of Revenue | $264.35B |
| Gross Profit | $12.36B |
| SG&A Expenses | $7.78B |
| Operating Expenses | $7.98B |
| Operating Income | $4.38B |
| Interest Expense | $248.00M |
| Net Income | $3.56B |
| EPS (Basic) | $25.23 |
| EPS (Diluted) | $25.03 |
| Shares Outstanding (Basic) | 141.10M |
| Shares Outstanding (Diluted) | 142.20M |
Key Highlights
- 1McKesson completed significant divestitures in Europe, streamlining its operations and focusing on core markets.
- 2The company acquired Rx Savings Solutions, LLC, enhancing its Prescription Technology Solutions (RxTS) segment with affordability and adherence capabilities.
- 3A strategic partnership was formed with HCA Healthcare to create SCRI Oncology, LLC, aimed at advancing cancer care and clinical research.
- 4Revenues increased by 5% to $276.7 billion, driven by growth in the U.S. Pharmaceutical segment.
- 5Diluted earnings per share from continuing operations increased significantly to $25.05, up from $7.26 in the prior year.
- 6McKesson returned $3.9 billion to shareholders through share repurchases ($3.6 billion) and dividends ($292 million).
- 7The company continues to manage its significant opioid-related litigation liability, with an estimated accrued liability of $7.2 billion at March 31, 2023.